CIBC World Market’s NovoCure NVCR Stock Holding History

CIBC World Market’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,439	Closed	-$1.81M	–	1372
2020 Q4	$1.81M	Buy	10,439 +5,481	+111%	+$750K	0.01%	593
2020 Q3	$552K	Buy	+4,958	New	+$396K	﹤0.01%	796

Other funds holding NVCR

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CIBC World Market's NVCR Position: Q1 2021 in Review

CIBC World Market sold out of NovoCure (NVCR) in Q1 2021, closing a stake of 10,439 shares — an estimated $1.81M sold.

CIBC World Market first reported a position in NVCR in Q3 2020 and held it in 2 quarters. The position peaked at $1.81M in Q4 2020. 327 funds tracked by Wall St. Rank hold NVCR as of Q1 2021.

CIBC World Market reported no remaining NovoCure position as of Q1 2021 after selling out during the quarter.
CIBC World Market sold 10,439 NovoCure shares in Q1 2021, an estimated $1.81M.
CIBC World Market first reported a position in NovoCure in Q3 2020 and held it in 2 quarters.
CIBC World Market's NovoCure position peaked at $1.81M in Q4 2020.
327 funds tracked by Wall St. Rank held NovoCure as of Q1 2021.

Based on CIBC World Market's 13F filing for Q1 2021, filed 11 May 2021.